Abstract: Pharmaceutical compositions, kits and methods for treating tumors such as glioma and cancers such as leukemia with (R)-2-hydroxyglutarate (R-2HG) are provided, along with therapeutic regimens including treatment of a patient suffering from glioma or leukemia with a MYC-signaling inhibitor followed by or cotemporaneous with treatment with R-2HG, and optionally other chemotherapeutic agents.
Abstract: The invention provides for methods of treating autism associated with Desulfovibrio overgrowth in the gastrointestinal tract of a patient, said method comprising administering to the patient suffering from said autism a treatment course of aztreonam in an amount effective to treat autism in the patient, thereby treating autism.
Type:
Grant
Filed:
November 16, 2018
Date of Patent:
November 16, 2021
Assignee:
United States Government As Represented By The Department of Veterans Affairs
Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
Abstract: Provided is a method of treating and/or preventing Wolfram Syndrome (WS)-related neurodegeneration (i.e. of Wolfram Syndrome-Associated Neuronal Degeneration), by increasing the expression and/or functional activity of p21. A method of screening for pharmacological agents useful in treating and/or preventing such conditions is also provided.
Abstract: The present invention relates to a use for preventing, alleviating or treating a demyelinating disease by administering a pharmaceutical composition containing a carbamate compound of chemical formula 1.
Abstract: The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for 4-aminophenol derivatives, which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes.
Abstract: The invention relates generally to compositions and methods for the detection of zinc. In particular, compositions and methods are provided to detect changes in cellular zinc concentration and to correlate them to cellular phenomena.
Type:
Grant
Filed:
February 20, 2018
Date of Patent:
September 21, 2021
Assignee:
Northwestern University
Inventors:
Emily L. Que, Thomas V. O'Halloran, Teresa K. Woodruff
Abstract: A fungicidal composition comprising a mixture of components (A) and (B), wherein components (A) and (B) are as defined in claim 1, and use of the compositions in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.
Type:
Grant
Filed:
February 14, 2018
Date of Patent:
September 21, 2021
Assignee:
Syngenta Participations AG
Inventors:
Laura Quaranta, Stephan Trah, Matthias Weiss, Farhan Bou Hamdan
Abstract: This disclosure demonstrates that inhibition of Sirt5 can suppress malignant transformation of cells. Therefore, methods of treating cancer based on inhibition of Sirt5 are disclosed.
Abstract: The present invention provides 4-anilino-3-quinolinecarbonitriles compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib.
Abstract: The present invention relates to the use of compounds of the formula (I) in which R1, R2, R3, n, X and Y have the meanings given in the description, for controlling animal pests, in particular insects and/or spider mites and/or nematodes, by drenching the soil, by drip application to the soil, by immersing roots, tubers or bulbs, or by soil injection or for treating seed.
Type:
Grant
Filed:
March 31, 2015
Date of Patent:
July 13, 2021
Assignee:
BAYER CROPSCIENCE AKTIENGESELLSCHAFT
Inventors:
Bernd Alig, Silvia Cerezo-Galvez, Reiner Fischer, Adeline Köhler, Julia Johanna Hahn, Peter Lösel, Olga Malsam
Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.
Type:
Grant
Filed:
April 14, 2013
Date of Patent:
July 6, 2021
Assignee:
INTRA-CELLULAR THERAPIES, INC.
Inventors:
Sharon Mates, Robert Davis, Kimberly Vanover
Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.
Abstract: The present invention relates to a method of treating a patient with a serine/threonine kinase inhibitor wherein resistance to the treatment with a serine/threonine kinase inhibitor is suppressed by administering the serine/threonine kinase inhibitor on an intermittent dosing schedule.
Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases. The invention provides new compounds having improved solubility and/or potency, and methods for their use. In various aspects, the invention relates to the treatment of cancer. The invention provides methods for chemoprevention and prevention of tumor recurrence or metastasis. The invention further provides diagnostic techniques for treatment for certain cancer types. The invention utilizes specific inhibitors of CDK8/19 and/or measurement of CDK8 levels in a patient.
Abstract: A group of chiral conjugates (optically active hybrid molecules) of oligoetherpolyol structure are inhibitors of ATP-dependent reverse transporters of cells (OEP inhibitors). An OEP inhibitor is a conjugate having an equimolar ratio of optically active polyoxypropylene hexol and polyoxypropylene glycol. The produced preparation increases the efficacy of medicines by inhibiting multi-drug resistance mechanisms of cells. It may be used in biology, pharmacology, pharmaceutics, medicine, and agriculture. The inhibitor is produced by hydroxypropylation of a mixture of sorbitol and a bifunctional oxygen-containing compound in the presence of a hydroxide of an alkaline or alkaline earth metal. The bifunctional oxygen-containing compound used may be water, propylene glycol, dipropylene glycol, tripropylene glycol, tetrapropylene glycol, pentapropylene glycol, hexapropylene glycol, heptapropylene glycol or a mixture thereof.
Type:
Grant
Filed:
April 30, 2019
Date of Patent:
April 27, 2021
Assignees:
AO “Tatkhimfarmpreparaty”, Kazan Federal University
Inventors:
Yurij G. Shtyrlin, Al'fiya G. Iksanova, Yurij V. Badeev, Konstantin V. Balakin
Abstract: A fungicidal composition comprising a mixture of components (A) and (B), wherein component (A) defined by formula (I) is a 3,4-dihydroisoquinoline having a 1-benzimidazolyl substituent and component (B) is selected from difenoconazole, hexaconazole, azoxystrobin, fludioxonil, cyprodinil, fluazinam, isopyrazam, pyroquilon, tricyclazole, chlorothalonil, propiconazole, penconazole, fenpropimorph, fenpropidin, sulphur and Bacillus subtilis var. amyloliquefacien s Strain FZB24. The use of the composition in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.
Type:
Grant
Filed:
September 21, 2017
Date of Patent:
April 6, 2021
Assignee:
SYNGENTA PARTICIPATIONS AG
Inventors:
Farhan Bou Hamdan, Laura Quaranta, Matthias Weiss, Stephan Trah
Abstract: The present disclosure provides methods for killing the SARS CoV-2 virus in mammals and treating the Coronavirus Disease-19 (Covid-19) in mammals including humans using compositions including protocatechuic acid. The present disclosure provides methods and pharmaceutical and nutraceutical compositions that reduce or substantially eliminate the SARS CoV-2 virus in mammals. In one embodiment, a method of treating a mammal with Covid-19 is provided comprising administering protocatechuic acid to a mammal in need of such treatment a therapeutically effective amount of a protocatechuic acid composition.
Abstract: This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.
Abstract: This invention relates to the use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for the manufacture of a medicament for the treatment of a subject being infected with HIV, wherein the formulation is to be administered intermittently at a time interval of at least one week.
Type:
Grant
Filed:
January 19, 2007
Date of Patent:
March 23, 2021
Assignee:
Janssen Sciences Ireland Unlimited Company
Inventors:
Lieven Elvire Colette Baert, Guenter Kraus, Gerben Albert Eleutherius Van ′T Klooster